Gene Editing for Obesity: Can CRISPR Replace Ozempic?

The Ozempic Revolution — and Its Achilles Heel

In the span of just a few years, a class of drugs known as GLP-1 receptor agonists has fundamentally changed how medicine thinks about obesity. Semaglutide, sold as Ozempic for diabetes and Wegovy for weight loss, along with tirzepatide (Mounjaro and Zepbound), has delivered something doctors had struggled to achieve for decades: reliable, significant, sustained weight loss in the majority of patients who take it.

The numbers are striking. In the landmark STEP 1 clinical trial, patients taking semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to just 2.4% for the placebo group. Tirzepatide pushed the envelope further, with the SURMOUNT-1 trial showing average weight loss of up to 22.5% at the highest dose. For a patient weighing 250 pounds, that translates to losing more than 55 pounds — results that had previously been achievable only through bariatric surgery.

These drugs work by mimicking a natural hormone called GLP-1 (glucagon-like peptide-1), which the gut releases after eating. GLP-1 signals the pancreas to produce insulin, slows the emptying of the stomach, and — critically — acts on the brain to reduce appetite and increase the feeling of fullness. Tirzepatide goes further by also activating the GIP (glucose-dependent insulinotropic polypeptide) receptor, amplifying the metabolic effects.

The medical community has embraced these drugs with an enthusiasm bordering on awe. "GLP-1 receptor agonists are the most significant advance in obesity medicine in my career," said Dr. Robert Kushner, a professor of medicine at Northwestern University and a leading obesity researcher. "For the first time, we have medications that produce weight loss approaching what we see with surgery."

But there is a catch — a very expensive, very inconvenient one.

The Lifelong Commitment Problem

GLP-1 drugs are not a cure. They are a treatment that requires indefinite continuation. When patients stop taking semaglutide or tirzepatide, the weight comes back. In the STEP 1 trial extension study, published in the journal Diabetes, Obesity and Metabolism, participants who discontinued semaglutide regained roughly two-thirds of their lost weight within a year. Their appetite returned, their metabolic benefits faded, and their cardiometabolic risk factors worsened.

This is not a failure of the drugs — it reflects a fundamental biological reality. Obesity is a chronic disease driven by complex interactions between genetics, hormones, neural circuits, and environment. GLP-1 drugs suppress appetite and alter metabolism for as long as you take them. Stop the drug, and the underlying biology reasserts itself, just as blood pressure rises again when you stop taking antihypertensives.

The implications are financial and practical. In the United States, a month's supply of Ozempic or Wegovy carries a list price of approximately $1,000 to $1,350. That works out to $12,000 to $16,000 per year — every year, for the rest of a patient's life. Even with insurance coverage and manufacturer discounts, the costs remain substantial for many patients. And insurance coverage itself is uneven: many insurers and employers have been reluctant to cover weight loss medications, citing the cumulative expense of treating a condition that affects over 40% of American adults.

The numbers are staggering at a population level. Morgan Stanley analysts have estimated that the GLP-1 drug market could reach $105 billion in annual sales by 2030. Goldman Sachs has projected that up to 70 million Americans could be taking these drugs by the early 2030s. The societal cost of supplying a chronic, weekly injectable to tens of millions of people indefinitely is enormous — even if the drugs themselves are worth every penny in terms of health outcomes.

All of which raises a tantalizing question: What if you could achieve the same biological effect with a single treatment that lasts forever?

Enter Gene Editing: The One-Shot Obesity Cure Concept

The idea behind gene editing for obesity is conceptually the same as what is already being pursued for cholesterol. Just as companies like Verve Therapeutics and CRISPR Therapeutics are developing single-injection gene editing treatments to permanently lower LDL cholesterol by editing genes in the liver, a parallel approach could theoretically be applied to the metabolic pathways that control appetite, fat storage, and energy expenditure.

The most direct strategy would involve editing genes that influence the GLP-1 signaling pathway to permanently boost the body's own production of GLP-1 or to enhance the sensitivity of GLP-1 receptors. If your cells were edited to produce more GLP-1 on their own, or to respond more powerfully to the GLP-1 they already produce, you might achieve the appetite-suppressing, metabolism-boosting effects of Ozempic — without ever picking up a needle.

This is not a distant fantasy. Several research groups and biotech companies are actively exploring gene editing approaches to metabolic disease, and the proof-of-concept work in cardiovascular disease is paving the way.

Verve Therapeutics: Proof-of-Concept for Metabolic Gene Editing

To understand why gene editing for obesity is plausible, it helps to look at what is already working for a related metabolic condition.

Verve Therapeutics, now part of Eli Lilly following a $1.3 billion acquisition, has demonstrated that you can use base editing to permanently disable the PCSK9 gene in human liver cells, achieving durable cholesterol reductions of 53-69% with a single intravenous infusion. The Phase 1b clinical data from Verve's VERVE-102 program showed LDL cholesterol reductions that rival what PCSK9 inhibitor drugs achieve — but from one dose instead of injections every two to four weeks.

The mechanism is straightforward: lipid nanoparticles deliver base editing machinery to the liver, where it makes a precise single-letter change in the DNA of hepatocytes. The edited cells produce less PCSK9 protein, which means more LDL receptors stay active on the cell surface, pulling cholesterol out of the bloodstream.

Eli Lilly's willingness to pay $1.3 billion for this technology was a powerful signal. The pharmaceutical giant saw that one-time gene editing could disrupt the market for chronic metabolic medications — a market in which Lilly itself is a major player with tirzepatide. If the same approach could be applied to obesity-related targets, the commercial and medical implications would be even larger.

"The Verve acquisition validates the broader thesis that liver-directed gene editing can address chronic metabolic disease," said Dr. Kiran Musunuru, a cardiologist and geneticist at the University of Pennsylvania who has been a pioneer in PCSK9 gene editing research. "The liver is the body's metabolic command center, and editing it once could replace medications that patients would otherwise need for decades."

CRISPR Therapeutics' Metabolic Programs

CRISPR Therapeutics, the company co-founded by Nobel laureate Emmanuelle Charpentier, is pursuing its own metabolic gene editing programs — and the results are already making headlines.

In 2025, CRISPR Therapeutics reported positive Phase 1 data for CTX310, a one-time CRISPR-based therapy that disables the ANGPTL3 gene in the liver. ANGPTL3 is a protein that raises levels of LDL cholesterol, triglycerides, and other lipids. Naturally occurring loss-of-function mutations in ANGPTL3 are associated with dramatically lower cardiovascular risk and no apparent health consequences — making it an ideal target for therapeutic gene editing.

The clinical data, published in the New England Journal of Medicine, showed that a single infusion of CTX310 reduced triglyceride levels by up to 60% and LDL cholesterol by up to 50% in patients with elevated lipids. Dr. Steven Nissen, a renowned cardiologist at the Cleveland Clinic and principal investigator of the trial, described the results as "a proof of concept for the entire field of in vivo gene editing."

What makes CRISPR Therapeutics' work relevant to obesity is the company's broader ambition. CRISPR Therapeutics has publicly stated its interest in applying its liver-directed gene editing platform to multiple metabolic targets. While the company has not announced a specific obesity program, the infrastructure — lipid nanoparticle delivery to the liver, validated gene editing constructs, clinical manufacturing experience — is directly applicable.

CRISPR Therapeutics is also developing CTX340, targeting lipoprotein(a), or Lp(a), another genetically determined cardiovascular risk factor. Each new target the company validates strengthens the case that liver-directed gene editing is a generalizable platform for metabolic disease — including, potentially, obesity.

Academic Research: Editing the Genes of Appetite and Metabolism

While the clinical programs at Verve and CRISPR Therapeutics focus on cardiovascular targets, academic researchers are already exploring gene editing approaches that aim more directly at obesity.

The GLP1R Gene

The GLP-1 receptor gene (GLP1R) is an obvious candidate. Certain naturally occurring variants in GLP1R are associated with lower body weight and reduced risk of type 2 diabetes. A 2021 study published in Science identified specific GLP1R variants that appear to enhance receptor signaling, essentially making the body more responsive to its own GLP-1. People who carry these variants tend to be leaner and have better glucose control — they are, in a sense, living on a natural, built-in version of Ozempic.

"What we see in the genetics is that enhanced GLP-1 receptor signaling is protective against obesity and diabetes," said Dr. Luca Lotta, a geneticist at Regeneron Genetics Center and co-author of the study. "This raises the possibility that gene editing could be used to introduce similar beneficial variants into the GLP1R gene."

The challenge is that GLP1R is expressed not in the liver but primarily in the pancreas, gut, and brain — tissues that are much harder to reach with current gene editing delivery technologies. Lipid nanoparticles have a natural tropism for the liver, which is why liver-directed editing has advanced fastest. Reaching the brain with gene editing tools remains one of the field's greatest unsolved problems.

PCSK9 and Beyond: The Metabolic Cascade

Interestingly, some of the cardiovascular gene editing targets under development may also have benefits for obesity. PCSK9 and ANGPTL3, while primarily studied for their effects on cholesterol and lipids, are part of a broader metabolic network. Lowering triglycerides through ANGPTL3 editing, for example, could improve insulin sensitivity and reduce fat accumulation in the liver — a condition known as non-alcoholic fatty liver disease (NAFLD), which is closely linked to obesity.

Researchers at the Broad Institute of MIT and Harvard have been exploring whether editing multiple metabolic genes simultaneously — a concept sometimes called "multiplexed" gene editing — could produce synergistic benefits for patients with obesity and related metabolic conditions. The idea is that obesity is not a single-gene problem, so the solution may require editing multiple targets at once.

The MC4R Pathway

Another promising target is MC4R (melanocortin 4 receptor), a gene that plays a central role in regulating appetite in the brain. Loss-of-function mutations in MC4R are the most common genetic cause of severe early-onset obesity. Conversely, gain-of-function variants in MC4R are associated with lower body weight.

In 2023, researchers at the University of California, San Francisco demonstrated that CRISPR-based activation of MC4R in the hypothalamus of obese mice led to reduced food intake and significant weight loss. The study, published in Nature Metabolism, used an adeno-associated virus (AAV) vector to deliver CRISPR activation machinery to the brain — a delivery approach that, while still early-stage, showed that the concept of editing appetite-regulating genes is technically feasible.

"The MC4R pathway is essentially the brain's thermostat for body weight," said Dr. Christian Bhatt, an endocrinologist at UCSF. "If you can adjust that thermostat through gene editing, you could achieve durable weight management without chronic pharmacotherapy."

The $100 Billion Question: Market Forces Driving Gene Editing for Obesity

The economic case for a one-time gene editing treatment for obesity is overwhelming. Consider the math.

The global obesity drug market is projected to exceed $100 billion in annual revenues by 2030, driven almost entirely by GLP-1 receptor agonists. Novo Nordisk, the maker of Ozempic and Wegovy, became the most valuable company in Europe largely on the strength of semaglutide sales. Eli Lilly's stock price surged as tirzepatide sales exceeded expectations. The demand is enormous and growing, with manufacturers struggling to keep up with prescriptions.

But the chronic nature of these drugs means the cumulative cost is astronomical. A patient who starts Wegovy at age 40 and takes it for the remaining 40 years of their life would spend roughly $500,000 to $600,000 on the drug alone, at current prices. Multiply that by tens of millions of patients, and the societal burden becomes unsustainable — particularly for public health systems and insurers.

A one-time gene editing treatment, even priced at $50,000 to $100,000, would be dramatically cheaper over a patient's lifetime than decades of weekly injections. This is the same economic logic that has supported the pricing of gene therapies like Zolgensma ($2.1 million for spinal muscular atrophy) and Casgevy (approximately $2.2 million for sickle cell disease). If the treatment works permanently, a high upfront cost can still represent enormous savings compared to a lifetime of chronic therapy.

"The economic incentive to develop a one-shot treatment for obesity is larger than for any other condition in medicine," said Brad Loncar, a biotechnology investor and CEO of Loncar Investments. "The current model — weekly injections for life at a thousand dollars a month — is not sustainable at a population scale. Gene editing could fundamentally change that equation."

Challenges: Why This Is Harder Than It Sounds

Despite the compelling logic, a gene editing cure for obesity faces formidable scientific, regulatory, and ethical challenges. It is important to be honest about how far away this possibility is and what obstacles stand in the path.

Delivery Beyond the Liver

The biggest technical barrier is delivery. The liver is the easiest organ to reach with lipid nanoparticles because it naturally filters the blood and absorbs these particles. That is why liver-directed programs for cholesterol and lipid lowering have moved fastest. But many of the key genes involved in appetite regulation — including GLP1R, MC4R, and others — are expressed in the brain, pancreas, and gut.

Delivering gene editing tools to the brain in particular is extremely challenging. The blood-brain barrier, a highly selective membrane that protects the brain from toxins in the bloodstream, also blocks most therapeutic molecules, including lipid nanoparticles. AAV vectors can cross the blood-brain barrier to some degree, but they carry less genetic cargo than lipid nanoparticles and raise their own safety concerns, including immune reactions and the theoretical risk of insertional mutagenesis.

Until delivery technology catches up, gene editing for obesity will likely be limited to targets that are expressed in the liver — which may be sufficient for some metabolic benefits but probably cannot replicate the full appetite-suppressing, brain-mediated effects of GLP-1 drugs.

Irreversibility

GLP-1 drugs have an important safety feature: if a patient experiences severe side effects — nausea, pancreatitis, gallbladder problems — they can simply stop taking the medication, and the effects fade within days to weeks. Gene editing is permanent. Once a gene is edited, it cannot easily be unedited.

This irreversibility raises the safety bar enormously. For a life-threatening condition like sickle cell disease or severe familial hypercholesterolemia, the risk-benefit calculation may favor an irreversible treatment. But obesity, while a serious chronic disease, is not immediately life-threatening in most cases. Regulators and patients alike will demand an extraordinarily high standard of safety for an irreversible intervention targeting a condition that has multiple alternative treatments available.

"The irreversibility question is the single biggest challenge for gene editing in obesity," said Dr. Fyodor Urnov, a professor of genetics at the University of California, Berkeley and a pioneer in gene editing technology. "We need to be certain — not just hopeful, but certain — that the edit is safe before we deploy it at scale in a population of hundreds of millions."

Polygenic Complexity

Obesity is not a single-gene disease for the vast majority of people who have it. Unlike sickle cell disease, which is caused by a single mutation in one gene, common obesity is influenced by hundreds of genetic variants, each contributing a small effect, combined with environmental, behavioral, and psychological factors. Editing one gene — even an important one — may not produce sufficient weight loss to eliminate the need for other interventions.

The GLP-1 drugs work so well precisely because they act on a central signaling pathway that sits at the intersection of multiple metabolic processes. Replicating that effect through gene editing may require editing multiple genes or finding the right single target that produces an outsized downstream effect.

Ethics of Editing for Non-Life-Threatening Conditions

Gene editing has been developed and justified primarily in the context of devastating, often fatal diseases. Sickle cell disease, beta-thalassemia, muscular dystrophy — these are conditions where the suffering is acute, the alternatives are limited, and the ethical case for an aggressive intervention is clear.

Obesity occupies a more complicated ethical space. It is a genuine medical condition with serious health consequences, including increased risk of heart disease, diabetes, certain cancers, and reduced life expectancy. The WHO classifies obesity as a disease. But it is also deeply entangled with social attitudes about body size, personal responsibility, and beauty standards. Some critics worry that offering gene editing for obesity could reinforce harmful narratives about fatness as a defect that needs to be "fixed" at the genetic level.

There are also equity concerns. If a one-time gene editing treatment for obesity costs $50,000 to $100,000, who gets access? Will it be available only to the wealthy in developed countries, while the rest of the world continues to struggle with both the burden of obesity and the lack of affordable treatments?

What Is the Realistic Timeline?

Given all of these challenges, when might a gene editing treatment for obesity actually reach patients? Here is a realistic assessment.

Near-term (2025-2028): The liver-directed gene editing programs for cardiovascular disease — Verve's PCSK9 editing and CRISPR Therapeutics' ANGPTL3 editing — will continue through clinical trials. Their success or failure will heavily influence whether companies invest in extending the platform to obesity-specific targets. Positive data from these programs will accelerate interest; any serious safety signal will slow the entire field.

Medium-term (2028-2032): If liver-directed gene editing proves safe and effective for cholesterol, companies will begin preclinical and early clinical programs for obesity-related liver targets — for example, editing genes that influence hepatic fat metabolism, insulin sensitivity, or production of appetite-regulating hormones. These programs will likely focus on patients with severe obesity and related comorbidities, where the risk-benefit calculation most clearly favors an irreversible treatment.

Long-term (2032-2040): Advances in delivery technology — particularly the development of lipid nanoparticles, AAV variants, or other vectors that can efficiently reach the brain and pancreas — could open the door to editing appetite-regulating genes like GLP1R and MC4R. This would bring the possibility of a true one-shot alternative to GLP-1 drugs. But it requires solving the delivery problem, which is one of the hardest challenges in all of medicine.

"If you asked me to bet, I would say we will see the first gene editing treatments for metabolic disease — starting with cholesterol — approved within this decade," said Dr. Jennifer Doudna, the Nobel laureate who co-invented CRISPR-Cas9, in a 2024 interview. "Extending that to obesity will take longer, but the scientific foundation is being laid right now."

The Bigger Picture: One Shot vs. One Thousand Shots

The contrast between the current GLP-1 paradigm and the gene editing vision is stark. Today, a patient diagnosed with obesity faces a future of weekly injections, monthly pharmacy trips, insurance battles, and the ever-present knowledge that stopping treatment means regaining weight. It works, but it is a treadmill.

Gene editing promises a different model: a single treatment, administered once, that permanently recalibrates the body's metabolic machinery. No refills. No adherence challenges. No annual cost. The biology is changed at its source.

We are not there yet. The science is early, the challenges are real, and the path from laboratory proof-of-concept to approved clinical therapy is measured in years and billions of dollars. But the convergence of several forces — the validation of liver-directed gene editing in cardiovascular disease, the massive unmet need in obesity, the unsustainable economics of chronic GLP-1 therapy, and the rapid advance of delivery technologies — makes it increasingly likely that gene editing for obesity will move from idea to experiment to reality within the next decade or two.

The question is not whether scientists will try. They already are. The question is whether the biology, the technology, and the ethics will align to make it possible — and whether society is ready for a world where obesity can be treated with a single edit to the human genome.

For the 650 million adults worldwide living with obesity, and for the health systems that bear the cost of treating its consequences, the answer cannot come soon enough.

---

Sources

1. Wilding, J.P.H., et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine, 2021. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183

2. Jastreboff, A.M., et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine, 2022. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038

3. Wilding, J.P.H., et al. "Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide." Diabetes, Obesity and Metabolism, 2022. https://dom-pubs.pericles-prod.literatumonline.com/doi/10.1111/dom.14725

4. Nissen, S.E., et al. "Single Ascending Dose Study of CRISPR-Based In Vivo Gene Editing for Lipid Lowering." New England Journal of Medicine, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2501983

5. Musunuru, K., et al. "In Vivo CRISPR Base Editing of PCSK9 Durably Lowers Cholesterol in Primates." Nature, 2021. https://www.nature.com/articles/s41586-021-03534-y

6. Dewey, F.E., et al. "Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease." New England Journal of Medicine, 2017. https://www.nejm.org/doi/full/10.1056/NEJMoa1612790

7. Lotta, L.A., et al. "Human Gain-of-Function MC4R Variants Show Signaling Bias and Protect Against Obesity." Cell, 2019. https://www.cell.com/cell/fulltext/S0092-8674(19)30837-1

8. Akbari, P., et al. "Sequencing of 640,000 Exomes Identifies GLP1R Variants Associated with Protection from Obesity." Science, 2021. https://www.science.org/doi/10.1126/science.abf8683

9. Morgan Stanley Research. "Obesity: The GLP-1 Opportunity." Sector Report, 2023. https://www.morganstanley.com/ideas/obesity-drugs-glp1-market

10. Goldman Sachs Research. "The GLP-1 Drug Market Could Reach $100B by 2030." Equity Research, 2023. https://www.goldmansachs.com/insights/pages/the-glp-1-drug-market.html

11. Verve Therapeutics. "Verve Therapeutics Presents Updated Clinical Data from VERVE-102 Phase 1b heart-2 Trial." Press Release, 2025. https://www.vervetx.com/news-media/press-releases

12. Eli Lilly and Company. "Lilly to Acquire Verve Therapeutics." Press Release, 2025. https://investor.lilly.com/news-releases

13. CRISPR Therapeutics. "CRISPR Therapeutics Reports Positive Phase 1 Data for CTX310." Press Release, 2025. https://crisprtx.com/about-us/press-releases

14. World Health Organization. "Obesity and Overweight." WHO Fact Sheet, 2024. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight